Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CGEN vs CERS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CGEN Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)
CGEN Overall Winner
6-Pillar Tally: CGEN 3 – 3 CERS
Matrix Metrics: CGEN 8 – 2 CERS
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Cerus Corp (CERS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CGEN carries a Unified Composite Score of 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin), whereas CERS carries 54.4/100 (HOLD) at $1.90 (126.7x Forward P/E, -1.1% operating margin).
- Composite vs. Pillar Nuance: While CERS currently prints a higher short-term Unified Composite Score (54.4/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (41.3% vs. -1.1% operating margin) and revenue trajectory (+102.1% vs. +9.5% YoY).
- Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile CERS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CGEN vs CERS
CGEN
Head-to-Head Winner
Compugen Ltd
$2.02
-0.98% 1D
Market Cap
$193.2M
TTM Revenue
$76M
Forward P/E
12.4x
Beta / 30D Vol
1.44β · 62% Vol
Unified Composite Score
47.1
HOLD
Tech 44.0
Fund 52.0
Flow 54.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
CERS
Cerus Corp
$1.90
+2.15% 1D
Market Cap
$375.6M
TTM Revenue
$227M
Forward P/E
126.7x
Beta / 30D Vol
1.62β · 78% Vol
Unified Composite Score
54.4
HOLD
Tech 65.0
Fund 60.0
Flow 56.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (CGEN 3 – 3 CERS)
1. Valuation Multiples
CGEN
Forward P/E
12.4x
126.7x
Trailing P/E
5.2x
N/M
PEG Ratio
1.29x
N/M
EV / Revenue
2.5x
1.9x
2. Growth & Scale
CERS
Revenue Growth (YoY)
+102.1%
+9.5%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$76M
$227M
Market Cap
$193.2M
$375.6M
3. Profitability & Quality
CGEN
Gross Margin
86.2%
51.8%
Operating Margin
41.3%
-1.1%
Net Profit Margin
47.9%
-3.2%
Return on Equity (ROE)
57.2%
-10.7%
4. Balance Sheet & Cash Flow
CGEN
Cash Generation (TTM)
$32M EBITDA
$494,000
Cash Flow Margin
41.9% EBITDA Mgn
0.2%
Net Cash / Leverage
$4.3M Net Cash
$59M Net Debt (0.99x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CERS
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
89.7% (57th %ile)
44.4% (20th %ile)
Put/Call OI Skew
N/A
0.66x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
CERS
OpEx & R&D Intensity
44.9% of Rev ($34M)
52.9% of Rev ($120M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
High-Margin Pricing Power Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CGEN (8) vs CERS (2)| Institutional Metric | CGEN | CERS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $193.2M | $375.6M | CERS | |
| Trailing P/E Ratio | 5.2x | N/M | CGEN | |
| Forward P/E Ratio | 12.4x | 126.7x | CGEN | |
| Revenue Growth (YoY) | +102.1% | +9.5% | CGEN | |
| Operating Margin (TTM) | 41.3% | -1.1% | CGEN | |
| Net Profit Margin | 47.9% | -3.2% | CGEN | |
| Return on Equity (ROE) | 57.2% | -10.7% | CGEN | |
| 52-Week Range Position | 33% ($1–$3) | 22% ($1–$3) | CGEN | |
| Beta / 30D Volatility | 1.44β · 62% Vol | 1.62β · 78% Vol | CGEN | |
| Unified Institutional Score | 47.1 / 100 (HOLD) | 54.4 / 100 (HOLD) | CERS | |
| Trailing 12M Revenue (USD) | $76M | $227M | Scale | |
| Gross Profit Margin (TTM) | 86.2% | 51.8% | Quality | |
| PEG Ratio & EV / Revenue | 1.29x PEG · 2.5x EV/Rev | N/M PEG · 1.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $32M EBITDA ($4.3M Net Cash) | $494,000 ($59M Net Debt (0.99x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CGEN +16.95 pp
3M Horizon
CGEN +16.12 pp
6M Horizon
CGEN +3.62 pp
1Y Horizon
CGEN +5.89 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CGEN Revenue | CERS Revenue | CGEN Op. Margin | CERS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $20M | $80M | -130.5% | -72.3% | CERS |
| FY2019 | N/A | $90M | N/A | -70.6% | CERS |
| FY2020 | $0M | $110M | -1574.8% | -51.1% | CERS |
| FY2021 | $10M | $160M | -584.6% | -30.7% | CERS |
| FY2022 | $10M | $190M | -471.7% | -18.1% | CERS |
| FY2023 | $30M | $190M | -38.8% | -16.1% | CERS |
| FY2024 | $30M | $200M | -53.4% | -7.1% | CERS |
| FY2025 | $70M | $230M | 43.1% | -3.7% | CGEN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CGEN
BREAKDOWN
Current IV
89.7%
IV Percentile
57th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CERS
BREAKDOWN
Current IV
44.4%
IV Percentile
20th %ile
Put/Call OI Skew
0.66x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact CERS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CGEN Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
44.9% of Rev ($34M)
90D Engineering Disclosures
0 Published
CERS Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
52.9% of Rev ($120M)
90D Engineering Disclosures
0 Published
Investor FAQ CGEN vs CERS Key Questions & Quantitative Answers
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Cerus Corp (CERS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CGEN carries a Unified Composite Score of 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin), whereas CERS carries 54.4/100 (HOLD) at $1.90 (126.7x Forward P/E, -1.1% operating margin). Composite vs. Pillar Nuance: While CERS currently prints a higher short-term Unified Composite Score (54.4/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (41.3% vs. -1.1% operating margin) and revenue trajectory (+102.1% vs. +9.5% YoY). Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile CERS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CERS leads the Growth & Scale pillar: CGEN posts +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin), compared with CERS at +9.5% YoY revenue growth and +0.0% YoY earnings growth on $227M TTM revenue (51.8% gross margin, -1.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGEN cumulative revenue shifted +250.0% while CERS shifted +187.5%. In operating R&D and SG&A reinvestment, CGEN deploys 44.9% of Rev ($34M) (0 90-day corporate R&D disclosures) versus 52.9% of Rev ($120M) (0 disclosures) for CERS.
CGEN screens cheaper on headline valuation multiples. CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin), whereas CERS trades at 126.7x Forward P/E, N/M Trailing P/E, N/M PEG, and 1.9x EV/Revenue (0.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEN (57.2% ROE) versus CERS (-10.7% ROE) capital efficiency.
In options market volatility and institutional positioning, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk). By comparison, CERS carries 44.4% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.62β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CERS vs CGEN · Reverse Pair
CGEN vs VCYT
· Sector Peer
CERS vs VCYT
· Sector Peer
CERS vs BCRX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking